Organon’s price looks neat in a table: P/E 18.8x, earnings yield 5.3%, cash-flow yield 19.9%. Those metrics imply relatively high earnings and cash-flow yields.
The other math is louder. Revenue dropped to $6.2B in 2025 and net margin collapsed to 3.0% — a 10.5 percentage-point swing from the prior year. The stock's six-month return is +67.7%, but revenue has declined and margins have compressed.
"Interest Expense Interest expense decreased 18% and 14% for the three and six months ended June 30, 2026, compared to 2025, respectively, due to the repurchase and cancellation of approximately $419 million of the Company’s 5.125% notes due in 2031 (the “2031 Notes”) during the second and fourth quarters of 2025, mandatory prepayments to our term loans in the first quarter of 2026 and lower reference rates on our USD-denominated variable rate debt." (Organon & Co. / 10-Q 2026-07-31)
Management points to tangible steps that trimmed interest costs: bond repurchases, term-loan prepayments and lower reference rates pushed interest expense down. That helps the income statement, but the company's market capitalization is $3.5B while net debt is $8.1B.
(Embed: valuation snapshot)
"Combined global sales of Cozaar ® (losartan) and Hyzaar ® (losartan / hydrochlorothiazide), which are medicines for the treatment of hypertension, declined 10% and 3% for the three and six months ended June 30, 2026, compared to 2025, respectively, driven by decreased demand in various international markets." (Organon & Co. / 10-Q 2026-07-31)
Popular, legacy drugs are shrinking. Management blames softer demand in international markets, less favorable guidelines, supply issues and mandatory price cuts in China and Japan. Those forces show up in the profit line next.
"Gross profit decreased 3% and 5% for the three and six months ended June 30, 2026, compared to 2025, respectively, due to the impact of unfavorable volume, pricing and product mix and unfavorable foreign exchange." (Organon & Co. / 10-Q 2026-07-31)
So: top-line pressure, margin pressure and FX headwinds. R&D spend has eased — management reports a 5% drop in R&D costs for both three- and six-month periods thanks to restructuring and lower clinical activity — which helps short-term cash but removes a cushion beneath future growth narratives.
The bullish counterweight is cash generation. In the latest annual period, operating cash flow covered net income 3.74x, which explains why valuations based on cash yields look attractive even while earnings look thin.
Organon’s own scenarios underline how fragile the valuation outcome is to multiples, not just performance. Management’s three scenarios all assume near-flat revenue (CAGRs around +0.1–0.2%), but the exit P/E swings wildly — from 13.2x in the bear case to 83.4x in the bull case. The result: an enormous bull-to-bear spread driven almost entirely by the exit multiple the market assigns.
That is the tension investors face in a sentence: a company that converts earnings into cash and has cut financing costs, yet one whose core sales and margins are under repeat pressure and which still carries $8.1B of net debt against an $11.6B enterprise value. Numbers that look cheap on yield can still hinge on whether multiple expansion holds — and Organon’s scenarios make that dependency very plain.
Source: Organon & Co. filings (10-Q 2026-07-31) and company disclosures.